Welcome!

News Feed Item

Low T Center Comments On The Pending AndroGel Lawsuits Regarding The Safety Of Testosterone Replacement

SOUTHLAKE, Texas, Feb. 13, 2014 /PRNewswire/ -- A number of people have asked how the recent FDA inquiries into testosterone therapy, and the related lawsuits brought by AndroGel patients, effect Low T Center.  "The answer is that they don't really relate to the medicine we practice at Low T Center," says Dr. William Reilly, M.D., Executive Director of the physician practice group treating patients in Low T Centers.  "We are excited about the FDA's inquiry into alternative testosterone delivery models," says Reilly.  "Physicians have been administering testosterone injections in cases of medical necessity since the 1950's.  Clinical research places the therapeutic benefits of testosterone replacement therapy beyond question, in cases where the treatment is medically appropriate and properly managed.  The key, like any treatment," explains Reilly, "is to maintain effective protocols and closely monitor the patient's results, all in conformance with good medical practice."

(Logo: http://photos.prnewswire.com/prnh/20140213/DA65138LOGO)

Testosterone replacement therapy is the practice of replacing the body's hormone deficits with a medically normal level of testosterone.  Generally, there are two types of therapeutic alternatives.  The most established form of treatment is injection therapy.  However, gels and topical treatments (like AndroGel) have come into vogue in the past couple of years.  Recently the FDA announced that it was investigating gels and topicals after a study linked their use to increased incidence of heart attacks. 

"Gels and topical treatments rely on the patient to treat themselves, and rest on the concept of theoretical absorption rates, which may or may not play out in real life practice," warns Reilly, who trained at the Cleveland Clinic, and has been in medical practice for over thirty years.  Inconsistent absorption rates, and the dangers of self-administered treatments can cause inconsistent results, or abnormally elevated levels of testosterone, causing Reilly to shun their use.  Reilly also cautions against ongoing treatment without proper medical monitoring.  "We regularly advise patients against the use of gels and topicals.  Our treatment protocol at Low T Center involves a closely monitored regimen of injection therapy.  Basically, if you have certain symptoms corroborated by a clinically low level of testosterone, we will bring you up to normal and appropriately monitor your blood levels to ensure consistent levels." 

Low testosterone levels can lead to fatigue, inability to concentrate, as well as other symptoms.  "This is not normal aging," says Reilly, who is trained in age management medicine, and is himself a testosterone replacement patient.  "Our patients range in age from their mid-thirties to late fifties.  Before they received treatment, they were suffering,  Now, many lead normal lives." 

The AndroGel lawsuits, filed in US District Court in Illinois, each allege that a particular patient was prescribed AndroGel, when the patient did not have clinically low levels of testosterone.  The lawsuits allege a causal connection between the improper use of AndroGel and heart attacks or strokes suffered by the patient.  Rather than sue the prescribing physician, the plaintiffs in the lawsuits have sued the manufacturer of AndroGel.  They cite a recent study which attempts to correlate high testosterone levels with heart conditions.

"Testosterone replacement therapy is a serious medical treatment for a serious medical condition.  Our number one complaint is, 'You will not treat me,'" continues Reilly.  "Roughly one-half of the men who come in are not candidates for treatment under our protocol."  According to Reilly, this fact differentiates Low T Center patients from the patients involved in the lawsuits and the research study that prompted the FDA investigation.  "Generally, the patients involved in the study were given a prescription for testosterone and told to treat themselves.  There was inadequate documentation as to whether these men actually suffered from low testosterone (also called hypogonadism), and many were in their sixties and seventies with pre-existing heart conditions.  These individuals would not be candidates for treatment under Low T Center protocol," Reilly explains.  "Our protocol requires screening for contraindications, symptoms, and verification by comprehensive laboratory testing." 

Low T Center has an experience base of over 500,000 patient visits.  Dr. Reilly opines, "While testosterone self-administered in an uncontrolled manner could result in increased risk, many studies indicate that testosterone applied in a controlled manner is cardio-protective.  Our data at Low T indicates that we have not had any significant cardiac events related to testosterone treatment, even with patients with a prior history of cardiovascular disease."

For More Information Contact:

Dr. William Reilly, M.D.


Low T Center Corporate Offices


1920 East Highway 114


Southlake, Texas 76092


817-417-3800



Reference:

Gallagher v. AbbVie, Inc., et. al.


Case Number 1:14-cv-776


US District Court, Northern District of Illinois


Filed:  2/4/2014




Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes, Journal of Clinical Endocrinology & Metabolism, June 2010, Vol. 95(6):2536–2559      




Trends in Androgen Prescribing in the United States


JAMA, August 2013




Testosterone and Cardioprotection Against Myocardial Ischemia, Cardiovascular & Hematological Disorders-Drug Targets, 2007 Jun;7(2):119-25, PMID: 17584046

SOURCE Low T Center

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Daiya Industry will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Daiya Industry specializes in orthotic support systems and assistive devices with pneumatic artificial muscles in order to contribute to an extended healthy life expectancy. For more information, please visit https://www.daiyak...
SYS-CON Events announced today that Fusic will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Fusic Co. provides mocks as virtual IoT devices. You can customize mocks, and get any amount of data at any time in your test. For more information, visit https://fusic.co.jp/english/.
SYS-CON Events announced today that Keisoku Research Consultant Co. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Keisoku Research Consultant, Co. offers research and consulting in a wide range of civil engineering-related fields from information construction to preservation of cultural properties. For more information, vi...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
SYS-CON Events announced today that Interface Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Interface Corporation is a company developing, manufacturing and marketing high quality and wide variety of industrial computers and interface modules such as PCIs and PCI express. For more information, visit http://www.i...
Today companies are looking to achieve cloud-first digital agility to reduce time-to-market, optimize utilization of resources, and rapidly deliver disruptive business solutions. However, leveraging the benefits of cloud deployments can be complicated for companies with extensive legacy computing environments. In his session at 21st Cloud Expo, Craig Sproule, founder and CEO of Metavine, will outline the challenges enterprises face in migrating legacy solutions to the cloud. He will also prese...
SYS-CON Events announced today that Ryobi Systems will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ryobi Systems Co., Ltd., as an information service company, specialized in business support for local governments and medical industry. We are challenging to achive the precision farming with AI. For more information, visit http:...
SYS-CON Events announced today that Enroute Lab will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enroute Lab is an industrial design, research and development company of unmanned robotic vehicle system. For more information, please visit http://elab.co.jp/.
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...
SYS-CON Events announced today that Nihon Micron will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Nihon Micron Co., Ltd. strives for technological innovation to establish high-density, high-precision processing technology for providing printed circuit board and metal mount RFID tags used for communication devices. For more inf...
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
In his session at @ThingsExpo, Greg Gorman is the Director, IoT Developer Ecosystem, Watson IoT, will provide a short tutorial on Node-RED, a Node.js-based programming tool for wiring together hardware devices, APIs and online services in new and interesting ways. It provides a browser-based editor that makes it easy to wire together flows using a wide range of nodes in the palette that can be deployed to its runtime in a single-click. There is a large library of contributed nodes that help so...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
DevOps at Cloud Expo – being held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real r...
Your clients expect transactions to never fail, cloud access to be fast and always on, and their data to be protected - no exceptions. Hear about how Secure Service Container (SSC), an IBM-exclusive open technology, enables secure building and hosting of next-generation applications, both cloud and on-premises. SSC protects the full stack from external and insider threats, allows automatic encryption of data in-flight and at-rest, and is tamper-resistant during installation and runtime – with no...